Teijin Ltd (3401)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Teijin Ltd (3401) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013454
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.

Teijin Ltd (3401) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Teijin Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat 18
Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 19
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 20
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 21
Licensing Agreements 22
Teijin Enters into Licensing Agreement with Merz Pharma 22
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 23
Teijin Enters into Licensing Agreement with Radius Health 24
Merck Enters into Licensing Agreement with Teijin Pharma 25
Amgen Enters into Licensing Agreement with Teijin Pharma 26
Teijin Pharma Enters into Licensing Agreement with Versartis 27
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 28
Debt Offering 29
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 29
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 30
Acquisition 31
Teijin Acquires 10% Stake In Kyorin For US$197 Million 31
Teijin Ltd – Key Competitors 32
Teijin Ltd – Key Employees 33
Teijin Ltd – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Joint Venture 36
Recent Developments 37
Financial Announcements 37
May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37
Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38
Other Significant Developments 44
Sep 05, 2016: Teijin Publishes Integrated Report 2016 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teijin Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Teijin Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat 18
Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 19
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 20
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 21
Teijin Enters into Licensing Agreement with Merz Pharma 22
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 23
Teijin Enters into Licensing Agreement with Radius Health 24
Merck Enters into Licensing Agreement with Teijin Pharma 25
Amgen Enters into Licensing Agreement with Teijin Pharma 26
Teijin Pharma Enters into Licensing Agreement with Versartis 27
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 28
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 29
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 30
Teijin Acquires 10% Stake In Kyorin For US$197 Million 31
Teijin Ltd, Key Competitors 32
Teijin Ltd, Key Employees 33
Teijin Ltd, Other Locations 34
Teijin Ltd, Subsidiaries 34
Teijin Ltd, Joint Venture 36

★海外企業調査レポート[Teijin Ltd (3401)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsui Fudosan Co Ltd (8801):企業の財務・戦略的SWOT分析
    Mitsui Fudosan Co Ltd (8801) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • China Shanshui Cement Group Limited:企業の戦略・SWOT・財務情報
    China Shanshui Cement Group Limited - Strategy, SWOT and Corporate Finance Report Summary China Shanshui Cement Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Catholic University of Leuven:製薬・医療:M&Aディール及び事業提携情報
    Summary Catholic University of Leuven (KU Leuven) is a scientific research and educational service provider that provides bachelors degree, post graduate degree and doctorate degree programs. The university provides educational courses in the areas of psychology and educational sciences, arts, law, …
  • Denka Co Ltd (4061):企業の財務・戦略的SWOT分析
    Denka Co Ltd (4061) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Aurora Spine Corp (ASG):企業の製品パイプライン分析2018
    Summary Aurora Spine Corp (Aurora) is a medical equipment provider that offers surgical tools. The company offers novel solutions in the spinal implant market through a range of minimally invasive, and regenerative spinal implant technologies. It develops and distributes spinal implant products whic …
  • Collins Foods Ltd (CKF):企業の財務・戦略的SWOT分析
    Collins Foods Ltd (CKF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • DocCheck AG (AJ91):企業の財務・戦略的SWOT分析
    DocCheck AG (AJ91) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • HIL Limited (HIL):企業の財務・戦略的SWOT分析
    HIL Limited (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dr. August Oetker Kg:企業の戦略・SWOT・財務分析
    Dr. August Oetker Kg - Strategy, SWOT and Corporate Finance Report Summary Dr. August Oetker Kg - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ameresco Inc (AMRC):企業の財務・戦略的SWOT分析
    Ameresco Inc (AMRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sodexo Inc:企業の戦略的SWOT分析
    Sodexo Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • UGI Corporation (UGI)-石油・ガス分野:企業M&A・提携分析
    Summary UGI Corporation (UGI) is a holding company providing energy products and services. Through a network of subsidiaries, the company stores, transports, distributes and markets energy products and related services. It serves as a domestic and international retail distributor of propane and buta …
  • Holder Construction Co:企業の戦略的SWOT分析
    Holder Construction Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Grand Haven Board of Light and Power:企業の戦略的SWOT分析
    Grand Haven Board of Light and Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Alexion Pharmaceuticals Inc (ALXN)-製薬・医療分野:企業M&A・提携分析
    Summary Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic d …
  • Banco Popular Dominicano S.A.:企業の戦略・SWOT・財務情報
    Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Polenergia SA (PEP):電力:M&Aディール及び事業提携情報
    Summary Polenergia SA (Polenergia) formerly Polish Energy Partners SA develops, implements and operates projects related to production of electricity and fuels. It offers services such as project implementation and supervision of construction, management of power facilities, production and sales of …
  • Business Connexion Group Limited:企業の戦略的SWOT分析
    Business Connexion Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Ayala Corp (AC):企業の財務・戦略的SWOT分析
    Ayala Corp (AC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Vyome Biosciences Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Vyome Biosciences Pvt Ltd (Vyome) is a clinical-stage biopharmaceutical company that develops novel drugs for antibiotic-resistant acne, other skin pathogens and anti-fungal agents in dermatology. The company’s pipeline products include VB 1953, VB 6345, VB 9333 and VB 9450. Its products are …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆